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Summary Meta-tetrahydroxyphenylchlorin (m-THPC) and 5-aminolaevulinic acid (5-ALA) are two second-generation photosensitizers which
are currently under investigation for photodynamic therapy (PDT) and photodynamic diagnosis (PDD). So far, the experience with these
photosensitizers for use within brain tumours is limited. We examined the distribution and retention of 14C-labelled m-THPC and [14C]5-ALA in
the rat C6 glioma brain tumour model. After intraperitoneal injection of m-THPC (71 909 d.p.m. gl-1; 0.16 mg ml-' m-THPC; 0.3 mg kg-'), the
following activities were found after 36 h: brain tumour 223 664 d.p.m. g-1, brain contralateral to the tumour side 2567 d.p.m. g-1, liver
369 959 d.p.m. g-1 and skin 55 197 d.p.m. g-1; 100 000 d.p.m. corresponding to 0.22,g of m-THPC. After 7 days, the concentration of
m-THPC decreased to 76 277 d.p.m. g-1 in tumour and 635 d.p.m. g-1 in brain. The radioactivity after intravenous administration of [14C]5-ALA
(23 079 d.p.m. gI-1; 40 mg ml-'; 120 mg kg-') increased within 15 min (59 634 d.p.m. g-1 in tumour, 17 427 d.p.m. g-1 in brain); after 8 h only a
small amount (3653 d.p.m. g-1 in tumour) remained. Brain adjacent to the tumour was also found to have a higher uptake of 5-ALA. This study
provides basic information for the use of m-THPC and 5-ALA in brain tumours. Because of the different pharmacokinetic and toxicological
profile, we recommend m-THPC for PDT and 5-ALA for PDD. Clinical trials now have to prove the superior phototoxic properties of these
second-generation photosensitizers.
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Malignant brain tumours have an extremely poor prognosis.
Despite all attempts to improve the outcome, there has been only
little progress in the handling of these tumours. The current treat-
ment techniques (surgery, radiotherapy and chemotherapy) are
inadequate and new treatment modalities have to be found
(Komblith et al, 1993; Obwegeser et al, 1995).
Cerebral glioma is particularly suited to treatment with photo-
dynamic therapy (PDT) (Woodburn et al, 1992; Kostron et al,
1996). Most treatment failures are due to local recurrence. PDT as
a local therapy can avoid recurrences in other malignant tumours
(Cairnduff et al, 1994; Jocham, 1994; Szeimies and Landthaler,
1995; van Hillegersberg et al, 1995).
PDT has been used to kill glioma cells in vivo and in vitro, and
selective uptake of the first-generation photosensitizer haematopor-
phyrin derivate (HPD) into cerebral tumours has been demonstrated
(Wise and Taxdal, 1967; Kaye et al, 1985; Kostron et al, 1986).
PDT involves the administration of a photosensitizer and the
local illumination of the target with light of a wavelength corre-
sponding to the absorption peak of the administered drug. The
absorption of photon energy by the sensitizer, which is retained
with some selectivity in tumour tissue, induces a photochemical
reaction that most probably results in the generation of highly
reactive singled oxygen (102) (Gibson et al, 1984). Damage to
cellular components in close proximity to 102 leads to tumour cell
death, surrounding structures being spared.
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Although these assumptions promised a selective tumour
destruction ofhuman malignant glioma, the efficacy was somewhat
lower than estimated. Many studies have shown some effect (Kaye
et al, 1987; Kostron et al, 1988; Kaye, 1990; Muller and Wilson,
1990), however problems such as low penetration depth in human
brain, high skin photosensitivity that persists after treatment and
difficult instrumentation regimens occurred (Popovic et al, 1995;
Kostron et al, 1996). So far, haematoporphyrins have been used
almost exclusively as photosensitizers in clinical PDT (Woodbum
et al, 1992). Now, a second generation of sensitizers is emerging
with improved photophysical and phototoxic profiles for PDT.
The use ofendogenous porphyrins, which can be stimulated by
the application of 5-aminolaevulinic acid (5-ALA), has shown
particularly promising results with very low toxicity and, because
ofthe substance's short half-life, there is almost no clinically rele-
vant photosensitivity (Bedwell et al, 1992; Regula et al, 1994; van
der Veen et al, 1994).
Another encouraging new photosensitizer is meta-tetrahydroxy-
phenylchlorin (m-THPC). This compound is promising for the treat-
ment ofbrain tumours because ofthe absorption in the near-infrared
region, which supports a deep penetration of the stimulating light
into tumour tissue (Figure 1) (Bonnett and Berenbaum, 1989).
The aim ofthis study was to investigate and compare the uptake
of 5-ALA and m-THPC in brain tumour and normal tissue by
means ofradioactive labelled compounds in a rat glioma model.
MATERIALS AND METHODS
Tumour model
C6 glioma cells were grown at 37°C with 5% carbon dioxide and
97% humidity in RPMI-1640 medium supplemented with 10%
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Figure 1 Schematic diagram of the absorption spectra of metal-free
porphyrins and chlorins, in relation to the transmittance of 1 cm of human
tissue
fetal calf serum, 100 U ml-' penicillin and 100,ug ml strepto-
mycin. After trypsinization, 5 x 105 C6 glioma cells (volume 10 ,tl)
were injected at the coronar suture 2 mm from the midline
at a depth of 3 mm into the right frontal lobe of female
Sprague-Dawley rats (Himberg breeding laboratory, Vienna,
Austria) weighing approximately 160 g. For the implantation, the
rats were anaesthetized with ether. All rats were held in a 12-h dark!
12-h light schedule, examined for phototoxic reactions and killed
by ether overdose at the required time intervals.
All experiments were carried out in accordance with the proto-
cols approved by the Austrian Experimental Animal Committee,
conforming to European regulations.
Photosensitizer administration
The m-THPC powder was a gift from Scotia (Guildford, UK). It
was dissolved in a pharmaceutical solution of 20% ethanol, 30%
polyethylene glycol 400 and 50% water. To this solution, we
added '4C-labelled m-THPC (Efamol Research, Kentville, Nova
Scotia, Canada). The mixture was spectroscopically (Shimadzu
UV-180 spectrophotometer) verified to contain 0.16 mg m-l m-
THPC with 71 909 d.p.m. jl'.
Ten days after tumour injection, the animals received 0.3 mg kg-'
freshly prepared radioactive labelled m-THPC i.p., which corre-
sponded to about 0.3 ml injected volume. These rats were killed in
groups of at least four after 12, 24, 36, 48, 72, 96 and 168 h.
Radioactive labelled 5-ALA was obtained from New England
Nuclear (Vienna, Austria). The solution contained 3.7 MBq ml-'
[4-'4C]5-ALA. This solution was mixed with cold 5-ALA, which
was dissolved in phosphate-buffered saline to obtain a solution of
40 mg ml 5-ALA and 23 079 d.p.m. ul-'.
After 14 days, 120 mg kg-' (approximately 0.5 ml) of freshly
prepared solution was administered i.v. via the tail vein. The rats
were killed in groups of four after 5 min, 15 min, 30 min, 60 min,
120 min, 240 min and 480 min. Rats without sensitization served
as control.
Preparation of samples
After killing the rats, the brains as well as tumour, liver and skin
samples were removed. The brains were divided into cerebellum,
contralateral hemisphere, ipsilateral hemisphere and tumour. The
ipsilateral brain sample was the area adjacent to the tumour region
with a border of at least 2 mm to tumour tissue. Samples of
0.08 ± 0.05 g were removed, weighed, dissolved with 1.5 ml
Soluene 350 (Packard Instruments, Vienna, Austria) and kept at
50°C. After dissolution, 15 ml of Hionic Fluor (Packard
5) = Instruments) was added and the vials subjected to liquid scintilla-
tion counting (Canberra Packard Tri-Carb 2700).
All counts were corrected for quenching, using the transformed
spectral index of an external '33Ba source. With the exception of
the liver samples, the counting efficiency was between 92% and
95%. The samples with solubilized liver showed a colour quench
which reduced the efficiency to 88%. Five samples with pure
['4C]m-THPC solution, radioactive 5-ALA and scintillation fluid
were used as control and for calculations.
Statistics
Statistical analysis of data was performed using Friedman's test
for multiple comparisons of ranks of related samples. Single
comparisons were done by the Wilcoxon matched pairs test of
related samples. Values were calculated by the programme SPSS
for Windows version 6.1.3, P-values less than 0.05 were consid-
ered significant.
RESULTS
Investigations with mn-THPC
Background radioactivity was measured with corresponding
samples of two animals and five samples containing only scintilla-
tion fluid. All these samples showed a 14C radioactivity of less than
56 d.p.m. (mean 34 ± 13); five samples with 10gl of pure ['4C]m-
THPC solution showed a '4C radioactivity of 719 089 ± 52 869
d.p.m. Thirty-six hours afterm-THPC injection, the following activ-
ities were found in the contralateral and ipsilateral brain, cerebellum
and tumour:2567 d.p.m. g-', 5336 d.p.m g-, 5722 d.p.m. g-' and
223 664 d.p.m. g-' respectively. The concentrations after the other
time intervals are detailed in Figure 2A. All values in this figure are
mean values ± standard error, corrected for quenching and back-
ground radioactivity; to facilitate presentation, tumour values are
given as 1/10 ofreal values. The v-axis shows the disintegrations g-I
tissue; 100 000 disintegrations is equivalent to 0.22 jg ofm-THPC.
The maximum uptake was reached after 36 h in all of these tissues.
The amount of m-THPC in the tumour tissue was more than 80
times higher than in the contralateral brain between 36 h and 48 h
after the injection (223 664 vs. 2567 d.p.m. g-', ratio 87 after 36 h
and 192 206 vs. 1646 d.p.m. g-', ratio 117 after 48 h). In the brain
adjacent to the tumour, we could observe a higher uptake of m-
THPC than in the contralateral brain, but there was also a large
amount of m-THPC in the cerebellum. After 7 days, only a small
amount ofradioactivity was left in all ofthe tissues.
Figure 2B demonstrates the uptake ofm-THPC in liver, skin and
tumour. The uptake in the skin was clearly higher than in normal
brain tissue but did not reach the level of tumour tissue (after 36 h
55 197 d.p.m. g-I in skin vs. 223 664 d.p.m. g- in tumour).
The amount of m-THPC in the liver was higher than in tumour
tissue; however, the uptake in the liver was very fast and reached its
maximum after 24 h. In brain, the photosensitizer decreased during
the following days, and on day 7 only a small percentage of
radioactivity was left. For statistical confirmation we used a
Friedman two-way ANOVA model which showed a significantly
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higher uptake in tumour tissue than in contra- and ipsilateral brain
in all subgroups (P < 0.05, 12-168 h). Furthermore we could
observe a higher uptake of [14C]m-THPC in tumour in each sample.
The Wilcoxon test for matched pairs showed an overall signifi-
cance level ofP < 0.0001 in tumour vs. contra- or ipsilateral brain.
But there was no significant difference between contra- and ipsi-
lateral brain, although the 14C level of ipsilateral brain was clearly
higher after 24 and 36 h (mean 3075 vs. 2066 d.p.m. g-' after 24 h,
5336 vs. 2567 d.p.m. g-' after 36 h).
Investigations with 5-ALA
The 14C radioactivity of five pure 10 ,ul samples was 230 788 +
11 026 d.p.m., equivalent to 0.4 mg of 5-ALA. Figure 3A shows
the distribution of radioactivity in the 5-ALA group. The amount
of radioactivity found in contralateral and ipsilateral brain, cere-
bellum and tumour increased within the first 15 min; after 15-
30 min the radioactivity slowly decreased. After 8 h, only a small
amount of radioactivity was left in the tissues. The uptake in
tumour tissue was clearly elevated to the level in normal brain
(59 634 vs. 17 427 d.p.m. g-' after 15 min). Friedman's test
showed a P < 0.05 between 15 and 480 min, but was not signifi-
cant at 5 min. The brain to tumour ratio was best after 60 min and
reached a level of 1:5 (9127 vs. 46 304 d.p.m. g-' respectively).
The Wilcoxon test for matched pairs was significant between
tumour and contra- or ipsilateral brain (P < 0.0001), but, in
contrast to ['4C]m-THPC, also significant between contra- and
ipsilateral brain (P < 0.01). Figure 3B displays the uptake of
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Figure 2 (A) Amount of radioactivity in contralateral brain, ipsilateral brain, cerebellum and C6 glioma 12-168 h after [14C]m-THPC injection. To facilitate
presentation, tumour values are given as 1/10 of real values and different time intervals are separated by spaces. (B) Amount of radioactivity in C6 glioma, skin
and liver 12-168 h after [14C]m-THPC injection; different time intervals are separated by spaces
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Figure 3 (A) Amount of radioactivity in contralateral brain, ipsilateral brain, cerebellum and C6 glioma 5 min to 8 h after [14C]5-ALA injection. (B) Amount of
radioactivity in C6 glioma, skin and liver 5 min to 8 h after [14C]5-ALA injection
5-ALA in liver, skin and brain tumour. Liver tissue showed a high
radioactivity after 30 min (15 0281 d.p.m. g-'), with a slow
decrease in the following hours. The amount of 14C found in the
skin was similar to the radioactivity in tumour tissue, but was very
high after 15 min (128 245 d.p.m. g-I vs. 59 634 d.p.m. g-').
DISCUSSION
In this study, we examined the uptake of ['4C]m-THPC and [14C]5-
ALA in C6 glioma tissue and normal tissue. To ourknowledge, this
is the first study which measures and compares the uptake ofthese
photosensitizers in brain tumour tissue. As other authors have
shown for various other types of tumour by fluorescence studies
(Ris et al, 1993; van Geel et al, 1995; van Hillegersberg et al, 1995;
Mlkvy et al, 1996), we could demonstrate a significantly higher
uptake of m-THPC and 5-ALA in glioma tissue than in normal
brain; furthermore, we could find that levels ofthese substances are
also higher in tissue adjacent to the tumour, however the higher
uptake ofm-THPC did not reach statistical significance. As is well
known, malignant glial tumours have a tendency to infiltrate into
the surrounding brain tissue (Burger, 1990); this infiltration has
also been demonstrated for Sprague-Dawley rats, which we used in
our study (Chicoine and Silbergeld, 1995). The higher uptake we
observed might be due to this phenomenon and represent an uptake
ofphotosensitizer in the infiltrating malignant cells. In contrast, this
phenomenon might also be explained by the tumour oedema
surrounding glial tumours. This aspect was demonstrated by
Stummer et al (1993) for porphyrins.
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Figure 1 demonstrates the dependence of transmittance on exci-
tation wavelength in human tissue. The high excitation wavelength
and the relative potency of m-THPC allow a deep penetration of
light into the surrounding brain, resulting in a deep biological effect
with the aim of destroying the infiltrating malignant cells which
might be responsible for relapse ofbrain tumours (Burger, 1990).
Compared with the photosensitizing properties of porphyrins
(Kaye et al, 1985; Kostron et al, 1986) m-THPC has significantly
higher concentrations in our tumour model. We could find a
brain-tumour ratio ofover 1:80 between 36 and 48 h.
Other advantages of m-THPC are the lower uptake and toxicity
in skin, the higher phototoxicity to tumour tissue and its chemical
stability (Veenhuizen et al, 1994; Braichotte et al, 1995; van Geel
et al, 1995). We could confirm that m-THPC is absorbed to only a
small extent by the skin (Figure 2B). Like Ris et al (1993), we
could confirm that m-THPC is taken up by a smaller amount in
skin than in tumour. However, Peng et al (1995) demonstrated that
with a higher dose of m-THPC (1 mg kg-') the uptake in skin was
even slightly higher. Perhaps this is a dose-dependent effect and
not only a distribution effect as Peng et al stated.
Alian et al (1994) studied the kinetics of m-THPC in various
tissues and found that the reduction in tissue fluorescence between
two measurements at 24 and 48 h after i.v. drug administration was
greatest in the liver. In our series with radiolabelled m-THPC, this
marked decrease occurred between the 48th and 72nd hour. The
prolonged retention of m-THPC in the liver seen in this study may
well be due to the use of an intraperitoneal injection of the photo-
sensitizer. Although the same decrease is not seen only in the liver,
other tissues did not show the rapid uptake and the plateau-like
shape of the graph. This observation emphasizes Alian et al's
theory of m-THPC trapping in the liver and redistribution during
the first hours.
Our experiments showed a higher uptake of m-THPC in
tumours, but no clear difference between the uptake times in
tumour and brain tissue. This observation stresses the finding of
Ris et al (1993), who showed that the time-dependent toxicity in
tumour tissue is not due to a different pharmacokinetic profile in
tumour and normal tissue. Nevertheless, m-THPC and its metabo-
lites are able to destroy tumour cells without damage to normal
cells, and this affect should be increased by the high brain-tumour
ratio in our series.
The other substance of interest was 5-ALA. In contrast to m-
THPC, this substance is not a photosensitizer by itself, but is
converted into the active substance protoporphyrin IX (PPIX). 5-
ALA is normally present in all mammalian cells and is the first
committed intermediate in the haem biosynthesis pathway.
Exogenous 5-ALA bypasses the feedback control and can there-
fore induce an intracellular accumulation ofPPIX. Animal experi-
ments (Bedwell et al, 1992; Regula et al, 1994; van der Veen et al,
1994) have shown that certain types of tissue, especially tumours,
show PPIX fluorescence after i.v. administration. Kriegmair et al
(1996) found that PPIX is able to mark malignant cells in the
bladder. We could confirm that 5-ALA and metabolites accumu-
late in malignant brain tumours. The uptake of radiolabelled
5-ALA in C6 gliomas is very fast. Radioactivity is present after
5 min, and there is a high ratio ofbrain to brain tumour tissue after
15 min. However, there is also a very rapid uptake in the skin,
followed by a sharp decrease. Perhaps this phenomenon is due to
an activation of PPIX in the skin.
As PPIX has a low excitation wavelength, and therefore can
hardly be used to destroy deep-seated tumour cells, this substance
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is ofless interest in tumour treatment but ofhigh interest in visual-
izing brain tumours. Glioma is often very hard to distinguish from
normal brain tissue and, thus, 5-ALA can intraoperatively support
the decision as to whether to remove or leave suspicious tissue. In
glioma surgery, this may be an enormous help to the surgeon, as
Stummer et al (1998) have already shown.
CONCLUSION
To our knowledge, the kinetics of radiolabelled m-THPC and 5-
ALA have been measured and compared for the first time; thus,
this study provides basic information for choosing the optimal
timing for PDT and photodynamic diagnosis (PDD) with m-THPC
or 5-ALA in brain tumours and other cancers.
m-THPC might currently be the sensitizer of choice for the
treatment or combined diagnosis and treatment of malignant brain
tumours because of absorption at high wavelength and, thus, good
penetration, high tumour-normal tissue ratio and strong tumour
toxicity (high therapeutic ratio). Because of the low but relevant
skin toxicity combined with long half-life, m-THPC should not be
used only for diagnosis.
5-ALA, in contrast, has the advantage of short half-life with
very little skin toxicity and excellent fluorescence yield, but a
lower excitation wavelength. These properties make 5-ALA suit-
able for diagnostic applications, for example the visualization of
malignant brain tumours.
Our data show conclusively that m-THPC is a good candidate
for a second-generation photosensitizer for PDT in brain tumours
and that 5-ALA is highly suitable for PDD.
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